Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Rubraca
Rubraca
FDA Gives Clovis Oncology's Rubraca a Priority Review
Motley Fool
Wed, 01/15/20 - 11:06 pm
Clovis Oncology
Rubraca
FDA
priority review
Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan?
Fierce Pharma
Wed, 01/8/20 - 12:09 pm
Clovis Oncology
Rubraca
M&A
JPMHC 2020
Is Clovis Oncology Really a Buyout Candidate?
Motley Fool
Tue, 12/3/19 - 10:21 pm
Clovis Oncology
M&A
Rubraca
oncology
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Fierce Pharma
Sat, 10/12/19 - 12:32 pm
Clovis Oncology
Rubraca
NICE
UK
PARP inhibitors
Clovis shares plunge after downgrade raises questions on path forward
Biopharma Dive
Wed, 09/25/19 - 09:15 am
Clovis Oncology
Rubraca
Clovis investors feel more Lynparza pressure
EP Vantage
Thu, 08/8/19 - 10:51 am
prostate cancer
Lynparza
Rubraca
Clovis Oncology
AstraZeneca
Merck
Clovis investors lose faith as Rubraca struggles against Big Pharma's marketing giants
Fierce Pharma
Fri, 08/2/19 - 12:43 pm
Clovis Oncology
Rubraca
PARP inhibitors
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
Yahoo/Zacks.com
Thu, 04/18/19 - 10:25 pm
Clovis Oncology
Rubraca
ovarian cancer
Clovis down after discontinuing rucaparib bladder cancer trial
BioCentury
Fri, 04/12/19 - 11:48 pm
Clovis Oncology
Rubraca
bladder cancer
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
Tue, 04/2/19 - 04:22 pm
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
CP Wire
Tue, 12/4/18 - 09:36 am
Clovis Oncology
Europe
Rubraca
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
Tue, 12/4/18 - 09:13 am
Clovis Oncology
Rubraca
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October
Motley Fool
Tue, 11/6/18 - 11:50 pm
Clovis Oncology
Rubraca
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
BioCentury
Sat, 10/20/18 - 11:07 pm
Clovis Oncology
Rubraca
rucaparib
metastatic castration-resistant prostate cancer
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca for Metastatic Castration Resistant Prostate Cancer
CP Wire
Tue, 10/2/18 - 09:55 am
Clovis Oncology
Rubraca
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca for Metastatic Castration Resistant Prostate Cancer
Tue, 10/2/18 - 09:49 am
Clovis Oncology
Rubraca
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
Wed, 08/8/18 - 09:01 am
Clovis Oncology
Rubraca
Opdivo
ovarian cancer
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
CP Wire
Fri, 04/6/18 - 02:46 pm
Clovis Oncology
Rubraca
ovarian cancer
Pages
« first
‹ previous
1
2
3
next ›
last »